Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Yakobson

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Immunotherapy|May 10, 2021
Nivolumab-induced systemic capillary leak syndrome as an ultra rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacyIlya Polishchuk, Alexander Yakobson, Melanie Zemel, et al.
Frontiers in Oncology|March 3, 2020
Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective StudyReut Hadash-Bengad, Emma Hajaj, Shiri Klein, et al.
Cancers|July 24, 2021
Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)Walid Shalata, Muhammed Iraqi, Baisali Bhattacharya, et al.
Cancers|March 28, 2025
Is the Addition of Chemotherapy to Adjuvant Radiation in Merkel Cell Cancer Beneficial? Real-World Data with Long-Term Follow-UpWalid Shalata, Hanna T Frumin Edri, Ina Sarel, et al.
Frontiers in Molecular Biosciences|May 11, 2026
Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLCWalid Shalata, Bilal Krayim, Asmah Miari, et al.
Frontiers in Immunology|December 8, 2025
Worse prognosis of local and locally advanced head and neck Merkel cell carcinoma: Is it time to change the treatment paradigm?Ronen Brenner, Hanna T Frumin Edri, Ina Sarel, et al.
Diagnostics (Basel, Switzerland)|March 14, 2026
Sun-Exposed vs. Non-Sun-Exposed Areas: Epidemiology and Pathogenesis of Non-Metastatic Merkel Cell CarcinomaAlexander Yakobson, Ronen Brenner, Hanna T Frumin Edri, et al.
Frontiers in Molecular Biosciences|July 9, 2026
Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinibWalid Shalata, Bilal Krayim, Asmah Miari, et al.
International Journal of Molecular Sciences|February 13, 2026
Impact of Statin Use on Immunotherapy Outcomes and Efficacy in Non-Small Cell Lung Cancer PatientsAlexander Yakobson, Abed Agbarya, Yulia Dudnik, et al.
Biomedicines|March 28, 2026
Evaluating the Therapeutic Impact of Immune Checkpoint Inhibitors in the Management of Brain Metastases from Non-Small Cell Lung CancerKeren Rouvinov, Rashad Naamneh, Alexander Yakobson, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Immunotherapy|May 10, 2021
Nivolumab-induced systemic capillary leak syndrome as an ultra rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacyIlya Polishchuk, Alexander Yakobson, Melanie Zemel, et al.
Frontiers in Oncology|March 3, 2020
Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective StudyReut Hadash-Bengad, Emma Hajaj, Shiri Klein, et al.
Cancers|July 24, 2021
Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)Walid Shalata, Muhammed Iraqi, Baisali Bhattacharya, et al.
Cancers|March 28, 2025
Is the Addition of Chemotherapy to Adjuvant Radiation in Merkel Cell Cancer Beneficial? Real-World Data with Long-Term Follow-UpWalid Shalata, Hanna T Frumin Edri, Ina Sarel, et al.
Frontiers in Molecular Biosciences|May 11, 2026
Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLCWalid Shalata, Bilal Krayim, Asmah Miari, et al.
Frontiers in Immunology|December 8, 2025
Worse prognosis of local and locally advanced head and neck Merkel cell carcinoma: Is it time to change the treatment paradigm?Ronen Brenner, Hanna T Frumin Edri, Ina Sarel, et al.
Diagnostics (Basel, Switzerland)|March 14, 2026
Sun-Exposed vs. Non-Sun-Exposed Areas: Epidemiology and Pathogenesis of Non-Metastatic Merkel Cell CarcinomaAlexander Yakobson, Ronen Brenner, Hanna T Frumin Edri, et al.
Frontiers in Molecular Biosciences|July 9, 2026
Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinibWalid Shalata, Bilal Krayim, Asmah Miari, et al.
International Journal of Molecular Sciences|February 13, 2026
Impact of Statin Use on Immunotherapy Outcomes and Efficacy in Non-Small Cell Lung Cancer PatientsAlexander Yakobson, Abed Agbarya, Yulia Dudnik, et al.
Biomedicines|March 28, 2026
Evaluating the Therapeutic Impact of Immune Checkpoint Inhibitors in the Management of Brain Metastases from Non-Small Cell Lung CancerKeren Rouvinov, Rashad Naamneh, Alexander Yakobson, et al.
Pageof 7